Advertisement


Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

2017 ASTRO Annual Meeting

Advertisement

Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).



Related Videos

Prostate Cancer

William A. Hall, MD, on Prostate Cancer: Results From a Study of Three Treatment Modalities

William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, an...

Prostate Cancer
Kidney Cancer

Gerard Morton, MD, on GU Highlights: Expert Perspective

Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using...

Breast Cancer

Shulian Wang, MD, and Benjamin Movsas, MD, on Breast Cancer: Radiation Therapy After Mastectomy

Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after ma...

Gynecologic Cancers

Marcus E. Randall, MD, on Endometrial Cancer: Results From a Gynecology Oncology Group Study

Marcus E. Randall, MD, of the University of Kentucky, discusses phase III study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplati...

Lymphoma

Christopher R. Kelsey, MD, on DLBCL: Study Results on Consolidation Radiotherapy

Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II fi...

Advertisement

Advertisement



Advertisement